Skyhawk presents itself today on its new tarnish spray modulator tarn. Small Sky-0515 molecule Huntington Disease to members of Huntington Organization of young people from the disease at the annual hydo international congress in Prague, Czech Republic.
BOSTON,, March 15, 2025 / Prnewswire / – Skyhawk Therapeutics, Inc., A biotechnology company at a clinical stage developing new therapies of small molecules designed to modulate critical RNA targets, is now presented on its new tarnish tarnish modulator with small Sky-0515 molecule Huntington Disease to members of Huntington Organization of young people from the disease (HDYO), at the Biannual Hydo International Congress in Prague, Czech Republic.
Sky-0515 is the splicing modifier of the Skyhawk Small Molecule RNA developed by the new SPRA SPLING platform of the company. Sky-0515 is designed to reduce both the HTT protein and the PMS1 protein, an additional key engine of the CAG somatic repetition expansion and HD pathology.
“We are excited to present on our Huntingtin-Lowering Clinical Trials at the Hdyo International Congress this Month,” Said Sergey Paushkin, Chief Scientific Officer and Head of R & D at Skyhawk, “With Positive Results included Sky-0515’s Average Htt MRNA Reduction of 72% Oral dose of 9mg in trials Thus Far, and the drug’s predicted deletion of the pms1 protein, sky-0515, if approved, could make a significant difference in Huntington Patients’ lives. “”
Huntington Disease is a rare hereditary neurodegenerative disease affecting more than 40,000 patients The United States And many others in the world. There is no approved treatments that can reverse or slow down its progress.
“We are satisfied with the speed at which we have carried out our studies so far and we focus on this patient community in need,” said Bill HaneyCEO of Skyhawk. “Until now, the convincing results of Sky-0515 have so far demonstrated the immense potential of our platform to target the indications for which there are no therapies modified by the disease approved.”
On Skyhawk Therapeutics
Skyhawk Therapeutics is a biotechnology company at a clinical stage focused on the discovery and development of new therapies of small molecules designed to modulate critical RNA targets and revolutionize the treatment of patients for some of the most intractable diseases in the world. Skyhawk’s discovery expertise is rooted in its proprietary drug discovery platform, which assesses, identifies and tests RNA splicing targets and small molecules through a wide range of therapeutic areas and pathological states. Skyhawk has established collaborations with several pharmaceutical partners who exploit the new Skyhawk platform in disease areas, including neurodegenerative diseases, autoimmune diseases and oncology. For more information, visit www.skyhawktx.com.
Skyhawk contact
Maura McCarthy
maura@skyhawktx.com
Skyhawk therapeutics source
